GT Medical Technologies, Inc., a company focused on improving the lives of patients with brain tumors, today announced a publication of prospective, multicenter Phase IV data from the ongoing ...
CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today ...
Effective Patient Triaging: Prospective clinical data demonstrated a significant reduction in recall rates for low-risk cases, decreasing from 7.6% to 5.7%, which minimizes nonessential follow-up ...
Atrial fibrillation is the most common form of heart rhythm disorder and is linked to serious complications, including stroke and heart failure. While earlier research pointed to a possible ...
A large, multi-center study recently published online in the Journal of the National Comprehensive Cancer Network (JNCCN) ...
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Eligible patients ...
Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study. TACE with or without ...
Shriners Children’s is leading a multi-center study that they hope will improve standards of care for burn patients everywhere and could potentially lead to insurance companies changing their coverage ...